4 completed, 1 unknown, 1 withdrawn. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Arthroplasty, Replacement, Knee: new trials by email Literature Review of Arthroplasty, Replacement, Knee trials Research Report on Arthroplasty, Replacement, Knee
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin Sodium enoxaparin, Dimolegin, Dimolegin placebo - Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | Phase 3 | Completed | Avexima Diol LLC | 215 | 2024-07-22 | 2026-01-16 |
| COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement Cannabinol, Placebo oral capsule - Arthroplasty, Replacement, Knee | Phase 2 / Phase 3 | Unknown | Unity Health Toronto | 220 | 2020-05-01 | 2019-10-01 |
| The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty Evicel, tourniquet - Arthroplasty, Replacement, Knee | Phase 3 | Withdrawn | Montefiore Medical Center | 2015-10-01 | 2018-03-27 | |
| Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Sugammadex, neostigmine and glycopyrrolate or atropine, Placebo to neostigmine - Neuromuscular Blockade, Arthroplasty, Replacement, Hip | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1198 | 2011-10-12 | 2021-02-12 |
| RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery enoxaparin, dabigatran etexilate - Arthroplasty, Replacement, Knee, Thromboembolism | Phase 3 | Completed | Boehringer Ingelheim | 2101 | 2004-11-01 | 2014-05-19 |
| Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement Dabigatran Dose 1 - day 2 to completion, Dabigatran Dose 1 - day 1, Dabigatran Dose 2 - day 2 to completion - Arthroplasty, Replacement, Knee, Thromboembolism | Phase 3 | Completed | Boehringer Ingelheim | 2615 | 2004-11-01 | 2014-05-05 |
Thromboembolism (2) · Agnosia (1) · Hemorrhage (1) · Marijuana Abuse (1) · Thrombosis (1) · Venous Thromboembolism (1)
Cardiovascular Diseases (4) · Embolism and Thrombosis (4) · Vascular Diseases (4) · Pathological Conditions, Signs and Symptoms (2) · Chemically-Induced Disorders (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathologic Processes (1) · Perceptual Disorders (1) · Signs and Symptoms (1) · Substance-Related Disorders (1) · Thromboembolism (1)
Enoxaparin (3) · (+-)-(1'R*,2'S*,6'R*)-(2-hydroxy-4,6-dimethoxyphenyl)(3'-methyl-2'-(3''-methylbut-2''-enyl)-6-phenylcyclohex-3'-enyl)methanone (1) · Atropine (1) · Cannabinol (1) · Dabigatran (1) · Glycopyrrolate (1) · Medical Marijuana (1) · Neostigmine (1) · Sugammadex (1) · Tourniquets (1) · enoxaparin sodium (1)
Boehringer Ingelheim (2) · Avexima Diol LLC (1) · Merck Sharp & Dohme LLC (1) · Montefiore Medical Center (1) · Unity Health Toronto (1)
Canada (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Mexico (1) · Netherlands (1) · Poland (1) · Russia (1)
Amit Atrey, MD (1) · Sun Jin Kim, MD (1)
PMID 22709460, PMID 10565650, PMID 22623147, PMID 22995531, PMID 25208233
2004 (1)